Yestar Healthcare Holdings
Market Cap
HK$3.3b
Last Updated
2019/10/18 12:47 UTC
Data Sources
Company Financials +
Executive Summary
Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products; distribution of in vitro diagnostic products; and manufacture and sale of dental films in the People’s Republic of China.
Snowflake
Fundamentals
Fair value with acceptable track record.
Share Price & News
How has Yestar Healthcare Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.5%
2393
1.7%
HK Medical Equipment
0.8%
HK Market
1 Year Return
-32.5%
2393
11.8%
HK Medical Equipment
0.5%
HK Market
Return vs Industry: 2393 underperformed the Hong Kong Medical Equipment industry which returned 11.8% over the past year.
Return vs Market: 2393 underperformed the Hong Kong Market which returned 0.5% over the past year.
Shareholder returns
| 2393 | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.5% | 1.7% | 0.8% |
| 30 Day | -7.3% | -1.9% | -0.5% |
| 90 Day | 20.9% | 20.2% | -5.6% |
| 1 Year | -32.5%-32.5% | 13.0%11.8% | 4.1%0.5% |
| 3 Year | -67.5%-68.5% | 13.0%9.5% | 15.5%3.9% |
| 5 Year | -38.1%-41.3% | 2.6%-2.5% | 19.9%-0.2% |
Price Volatility Vs. Market
How volatile is Yestar Healthcare Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Did You Manage To Avoid Yestar Healthcare Holdings's (HKG:2393) Painful 68% Share Price Drop?2 weeks ago | Simply Wall St
Should You Like Yestar Healthcare Holdings Company Limited’s (HKG:2393) High Return On Capital Employed?1 month ago | Simply Wall St
Is Yestar Healthcare Holdings (HKG:2393) Using Too Much Debt?Valuation
Is Yestar Healthcare Holdings undervalued compared to its fair value and its price relative to the market?
48.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: 2393 (HK$1.39) is trading below our estimate of fair value (HK$2.72)
Significantly Undervalued: 2393 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2393 is good value based on its PE Ratio (10.5x) compared to the Medical Equipment industry average (15x).
PE vs Market: 2393 is poor value based on its PE Ratio (10.5x) compared to the Hong Kong market (10.3x).
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate 2393's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2393 is overvalued based on its PB Ratio (2.5x) compared to the HK Medical Equipment industry average (1.6x).
Next Steps
Future Growth
How is Yestar Healthcare Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
11.3%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2393's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if 2393's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2393's revenue (11.3% per year) is forecast to grow faster than the Hong Kong market (10.2% per year).
High Growth Revenue: 2393's revenue (11.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: 2393's Return on Equity is forecast to be high in 3 years time (27.4%)
Next Steps
Past Performance
How has Yestar Healthcare Holdings performed over the past 5 years?
20.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 2393's earnings have grown significantly by 20.7% per year over the past 5 years.
Accelerating Growth: 2393's earnings growth over the past year (5.4%) is below its 5-year average (20.7% per year).
Earnings vs Industry: 2393 earnings growth over the past year (5.4%) underperformed the Medical Equipment industry 50.2%.
Return on Equity
High ROE: Whilst 2393's Return on Equity (32.55%) is high, this metric is skewed due to their high level of debt.
Return on Assets
ROA vs Industry: 2393 has a higher Return on Assets than the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: 2393 has improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Yestar Healthcare Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 2393's short term assets (CN¥3.2B) exceeds its short term liabilities (CN¥2.9B)
Long Term Liabilities: 2393's short term assets (3.2B) exceeds its long term liabilities (1.8B)
Debt to Equity History and Analysis
Debt Level: 2393's debt to equity ratio (148.8%) is considered high
Reducing Debt: 2393's debt to equity ratio has increased from 22.7% to 148.8% over the past 5 years.
Debt Coverage: 2393's debt is not well covered by operating cash flow (19.2%).
Interest Coverage: 2393's interest payments on its debt are well covered by EBIT (5.6x coverage).
Balance Sheet
Inventory Level: 2393 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 2393's debt is covered by short term assets (assets are 1.824940x debt).
Next Steps
Dividend
What is Yestar Healthcare Holdings's current dividend yield, its reliability and sustainability?
5.08%
Forecast Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate 2393's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2393's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if 2393's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2393's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 2393 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2393's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
What is the CEO of Yestar Healthcare Holdings's salary, the management and board of directors tenure and is there insider trading?
4.2yrs
Average management tenure
CEO
James Hartono (43yo)
0yrs
Tenure
CN¥4,372,000
Compensation
Mr. James Hartono serves as the Chairman of The Board and Chief Executive Officer of Yestar International Holdings Company Limited. Mr. Hartono has over 12 years of experience in the distribution of image ...
CEO Compensation Analysis
Compensation vs. Market: James's total compensation ($USD617.78K) is about average for companies of similar size in the Hong Kong market ($USD299.33K).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.2yrs
Average Tenure
44.5yo
Average Age
Experienced Management: 2393's management team is considered experienced (4.2 years average tenure).
Board Age and Tenure
6.1yrs
Average Tenure
49.5yo
Average Age
Experienced Board: 2393's board of directors are considered experienced (6.1 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 67,500,000 |
| Max Price | CN¥1.07 |
| Entity | Individual |
| Role | Chief Executive Officer Chairman & CEO |
| Shares | 67,500,000 |
| Max Price | CN¥1.07 |
| Entity | Company |
| Shares | 230,000,000 |
| Max Price | CN¥1.79 |
Ownership Breakdown
Management Team
James Hartono (43yo)
Chairman & CEO
- Tenure: 0yrs
- Compensation: CN¥4.37m
Ying Wang (58yo)
Executive Director
- Tenure: 6.7yrs
- Compensation: CN¥2.00m
To Chan (60yo)
Executive Director
- Tenure: 7.7yrs
- Compensation: CN¥1.89m
Hong Wang (44yo)
CFO & Executive Director
- Tenure: 7.7yrs
- Compensation: CN¥988.00k
Ivan Ng (46yo)
Company Secretary
- Tenure: 4.4yrs
Chung Chan (43yo)
COO & Executive Director
- Tenure: 3.8yrs
- Compensation: CN¥2.28m
Changxiang Liao (44yo)
GM of Yestar Technology
- Tenure: 0yrs
Bin Li (45yo)
Chief Executive Officer of Shanghai Emphasis Investment Management Consulting Co Ltd
- Tenure: 4.2yrs
Board Members
James Hartono (43yo)
Chairman & CEO
- Tenure: 0yrs
- Compensation: CN¥4.37m
Ying Wang (58yo)
Executive Director
- Tenure: 6.7yrs
- Compensation: CN¥2.00m
To Chan (60yo)
Executive Director
- Tenure: 7.7yrs
- Compensation: CN¥1.89m
Hong Wang (44yo)
CFO & Executive Director
- Tenure: 7.7yrs
- Compensation: CN¥988.00k
Yiming Hu (55yo)
Independent Non-Executive Director
- Tenure: 6.1yrs
- Compensation: CN¥204.00k
Tirtamarta Karsono (71yo)
Independent Non-Executive Director
- Tenure: 6.1yrs
- Compensation: CN¥204.00k
Liky Sutikno (44yo)
Independent Non-Executive Director
- Tenure: 6.1yrs
- Compensation: CN¥204.00k
Chung Chan (43yo)
COO & Executive Director
- Tenure: 3.8yrs
- Compensation: CN¥2.28m
Company Information
Yestar Healthcare Holdings Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Yestar Healthcare Holdings Company Limited
- Ticker: 2393
- Exchange: SEHK
- Founded: 1971
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: HK$3.332b
- Shares outstanding: 2.38b
- Website: https://www.yestarcorp.com
Number of Employees
Location
- Yestar Healthcare Holdings Company Limited
- Green Land Building
- Floor 8, Block A
- Shanghai
- 201199
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 2393 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Oct 2013 |
Biography
Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products; distribution of in vitro diagnostic products; and ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/18 12:47 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.